Blog

This past week the American Journal of Psychiatry published an exciting new study “Stanford Accelerated Intelligent Neuromodulation Therapy for Treatment-Resistant Depression (SAINT),” which is highlighted in this recent piece in Inverse. We interviewed our Chief Services Officer and co-founder Owen Muir, MD, who was excited to explain how this treatment works, why it’s so important, and how...

An accelerated, high-dose transcranial magnetic stimulation (TMS) therapy significantly improved depression symptoms in a small, open-label study. (more…)

The Food and Drug Administration has approved a variant of the anesthetic and party drug ketamine for suicidal patients with major depression. (more…)

A new indication of Janssen’s ketamine based-nasal spray Spravato (intranasal esketamine) has been approved for rapid reduction of depression symptoms in those with major depressive disorder who have imminent risk of suicidal ideation, according to Houston-based psychiatrist Sandhya Prashad. “The original indication for treatment-resistant depression meant that patients had failed treatments...

An option for people who don’t see successful results from standard depression treatments like talk therapy or antidepressants is transcranial magnetic stimulation (TMS). Research shows that this non-invasive technique, which uses electromagnetic fields to stimulate nerve cells in the brain, can fill the therapeutic void left when other treatments fail. (more…)

In March 2019, intranasal esketamine—a form of ketamine marketed as SPRAVATO™ CIII Nasal Spray*—was approved by the U.S. Food and Drug Administration (FDA) to treat patients with treatment-resistant depression (TRD). James Murrough, MD, PhD, Director of Mount Sinai’s Depression and Anxiety Center for Discovery and Treatment, was deeply involved in the research that led to esketamine’s FDA...

For many people coping with major depressive disorder—which includes different types of depression that persist for at least two weeks—antidepressants can play an invaluable role in helping relieve symptoms, enabling them to resume the life they once enjoyed. But for those who experience a form known as treatment-resistant depression (TRD), standard medications tend to provide little to no...

It goes without saying that COVID-19 is on the minds of nearly every American. The societal and economic disruption is almost without precedent. As government officials and clinicians wrestle with issues of how to protect the public, there seem to be more questions than answers. The mental health effects of COVID-19 are as important to address as are the physical health effects. Social...

As the concern for the coronavirus continues to grow, we want to do our part to inform our patients on what we are doing to help keep you safe and provide continued treatment options during this time. (more…)

Over the course of the past 100 years, our understanding of depression has greatly expanded, as has the number of therapeutic options available to deal with it. One thing researchers have learned in the past century is that, in the vast majority of cases, there is no one single cause for depression. Instead, an array of risk factors typically play into the development of a person’s depressive...